Fulcrum has been left with no option but to abandon its ambitions for pociredir in SCD and “explore strategic alternatives.” (Photo by Sarah Silbiger/Getty Images) Fulcrum Therapeutics has scrapped ...
The oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain, anemia and organ damage and reduce life expectancy. Sign up here. Pociredir ...
Fulcrum Therapeutics (FULC) lost nearly 50% of its value in extended trading after the company disclosed plans to discontinue the development of its lead asset, pociredir, for sickle cell disease in ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
June 1 (Reuters) - Fulcrum Therapeutics (FULC.O), opens new tab said on Monday it would stop developing its experimental sickle-cell disease drug after the U.S. Food and Drug Administration raised ...
With few treatments available for sickle cell disease, encouraging early clinical data for a Fulcrum Therapeutics drug made it one to watch. But another medicine from the same drug class was recently ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Cambridge biotech notified ...
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik ® (tazemetostat) and the product’s subsequent global withdrawal on the benefit-risk ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company received FDA meeting ...
Supported Releases: These releases have been certified by Bloomberg’s Enterprise Products team for use by Bloomberg customers. Experimental Releases: These releases have not yet been certified for use ...
After discontinuing development of its lead asset, Fulcrum Therapeutics has provided more details on its restructure, with 48 of 57 employees headed out the door. Fulcrum Therapeutics’ restructure ...
A lever is a simple mechanism that uses a bar to pivot around a fixed point called a fulcrum. Levers can be joined together to form linkages. Simple linkages can be used to change the direction of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results